30 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
26 Feb 24
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
8:30am
requirements into 2027, including through clinical readouts from the ongoing SUMMIT, PEAK and APEX registration-directed trials.
R&D Expenses: Research … campaigns of bezuclastinib to continue supporting the company’s clinical trials. R&D expenses include non-cash stock compensation expense of $4.1
8-K
EX-99.1
COGT
Cogent Biosciences Inc
2 Nov 23
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
9:18am
will be sufficient to fund its operating expenses and capital expenditure requirements into 2026.
R&D Expenses: Research and development expenses were $50.1 … million for the third quarter of 2023 as compared to $29.9 million for the third quarter of 2022. R&D expenses include non-cash stock compensation
8-K
EX-99.1
COGT
Cogent Biosciences Inc
8 Aug 23
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
8:14am
expenditure requirements into 2026.
R&D Expenses: Research and development expenses were $38.9 million for the second quarter of 2023 as compared … trials and costs related to development of the research pipeline. R&D expenses include non-cash stock compensation expense of $3.6 million for the second
8-K
EX-99.1
COGT
Cogent Biosciences Inc
9 May 23
Cogent Biosciences Reports Recent Business Highlights and First Quarter
8:13am
equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into 2025.
R&D Expenses: Research and development … to costs associated with the on-going APEX, SUMMIT and PEAK clinical trials and costs related to development of the research pipeline. R&D expenses include
8-K
EX-99.1
COGT
Cogent Biosciences Inc
14 Nov 22
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
7:14am
costs associated with its newly-constructed Research Lab in Boulder, CO.
R&D Expenses: Research and development expenses were $29.9 million … for the third quarter of 2022 as compared to $14.8 million for the third quarter of 2021. R&D expenses include non-cash stock compensation expense of $2.1 million
8-K
EX-99.1
2abvf2
9 Aug 22
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
7:15am
8-K
EX-99.1
q3l9r
10 May 22
Cogent Biosciences Reports Recent Business Highlights and First Quarter
7:31am
8-K
EX-99.1
rei3l2r3w2nm14u5xxv
15 Mar 22
Cogent Biosciences Provides Corporate Updates, Fourth Quarter
8:08am
8-K
EX-99.1
5g9gs8ugqwj2
10 Nov 21
Cogent Biosciences Provides Corporate Updates and Reports Third Quarter 2021 Financial Results
8:05am
8-K
EX-99.1
2vt8d87q3cm e768o
16 Aug 21
Cogent Biosciences Provides Corporate Updates and Reports Second Quarter 2021 Financial Results
7:12am
8-K
EX-99.1
82lr8f4jo37zn1d4cqn
12 May 21
Cogent Biosciences Provides Corporate Updates and Reports First Quarter 2021 Financial Results
7:14am
8-K
EX-99.1
avx rf93r
16 Mar 21
Cogent Biosciences Reports Fourth Quarter 2020
7:15am
8-K
EX-99.1
rtwnutyl9i pbhlsu
9 Nov 20
Cogent Biosciences Reports Third Quarter 2020
7:33am
DEFM14A
wh8l2w
9 Oct 20
Proxy related to merger
4:44pm
8-K
EX-99.1
rksvwmrlt4wi4lcb
11 Aug 20
Unum Therapeutics Reports Second Quarter 2020
5:02pm